Serum 14-3-3η as predictor of clinical remission and progression of structural damage in early rheumatoid arthritis following a treat-to-target strategy in a randomized controlled trial

References

• Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet 2016;388:2023–38.
   PubMed Web of Science ®Google Scholar
• Atzeni F, Talotta R, Masala IF, Bongiovanni S, Boccassini L, Sarzi-Puttini P. Biomarkers in rheumatoid arthritis. Isr Med Assoc J 2017;19:512–6.
   PubMed Web of Science ®Google Scholar
• Zhao J, Li Z-G. The challenges of early diagnosis and therapeutic prediction in rheumatoid arthritis. Int J Rheum Dis 2018;21:2059–62.
   PubMed Web of Science ®Google Scholar
• Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580–8.
   PubMed Web of Science ®Google Scholar
• Zeng T, Tan L. 14-3-3η protein: a promising biomarker for rheumatoid arthritis. Biomark Med 2018;12:917–25.
   PubMed Web of Science ®Google Scholar
• Kilani RT, Maksymowych WP, Aitken A, Boire G, St-Pierre Y, Li Y, et al. Detection of high levels of 2 specific isoforms of 14-3-3 proteins in synovial fluid from patients with joint inflammation. J Rheumatol 2007;34:1650–7.
   PubMed Web of Science ®Google Scholar
• Maksymowych WP, Marotta A. 14-3-3η: a novel biomarker platform for rheumatoid arthritis. Clin Exp Rheumatol 2014;32:S35–9.
   Web of Science ®Google Scholar
• Maksymowych WP, van der Heijde D, Allaart CF, Landewé R, Boire G, Tak PP, et al. 14-3-3η is a novel mediator associated with the pathogenesis of rheumatoid arthritis and joint damage. Arthritis Res Ther 2014;16:1–11.
   Google Scholar
• Kadiri M, Charbonneau M, Lalanne C, Harper K, Balg F, Marotta A, et al. 14-3-3η promotes invadosome formation via the Foxo3–Snail axis in rheumatoid arthritis fibroblast-like synoviocytes. Int J Mol Sci 2022;23:123.
   Web of Science ®Google Scholar
• Hørslev-Petersen K, Hetland ML, Junker P, Pødenphant J, Ellingsen T, Ahlquist P, et al. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind. Ann Rheum Dis 2014;73:654–61.
   PubMed Web of Science ®Google Scholar
• Hørslev-Petersen K, Hetland ML, Ørnbjerg LM, Junker P, Pødenphant J, Ellingsen T, et al. Clinical and radiographic outcome of a treat-to-target strategy using methotrexate and intra-articular glucocorticoids with or without Adalimumab induction: a 2-year investigator-initiated, double-blinded, randomised, controlled trial (OPERA). Ann Rheum Dis 2016;75:1645–53.
   PubMed Web of Science ®Google Scholar
• van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 1999;26:743–5.
   PubMed Web of Science ®Google Scholar
• Bruynesteyn K, Boers M, Kostense P, van der Linden S, van der Heijde D. Deciding on progression of joint damage in paired films of individual patients: smallest detectable difference or change. Ann Rheum Dis 2005;64:179–82.
   PubMed Web of Science ®Google Scholar
• Maksymowych WP, Naides SJ, Bykerk V, Siminovitch KA, Van Schaardenburg D, Boers M, et al. Serum 14-3-3η is a novel marker that complements current serological measurements to enhance detection of patients with rheumatoid arthritis. J Rheumatol 2014;41:2104–13.
   PubMed Web of Science ®Google Scholar
• Plant MJ, Williams AL, O’Sullivan MM, Lewis PA, Coles EC, Jessop JD. Relationship between time-integrated C-reactive protein levels and radiologic progression in patients with rheumatoid arthritis. Arthritis Rheum 2000;43:1473–7.
   PubMed Web of Science ®Google Scholar
• Centola M, Cavet G, Shen Y, Ramanujan S, Knowlton N, Swan KA, et al. Development of a multi-biomarker disease activity test for rheumatoid arthritis. PLoS One 2013;8:e60635.
   PubMed Web of Science ®Google Scholar
• Brahe CH, Østergaard M, Johansen JS, Defranoux N, Wang X, Bolce R, et al. Predictive value of a multi-biomarker disease activity score for clinical remission and radiographic progression in patients with early rheumatoid arthritis: a post-hoc study of the OPERA trial. Scand J Rheumatol 2019;48:9–16.
   PubMed Web of Science ®Google Scholar
• Fedele AL, Petricca L, Tolusso B, Alivernini S, Canestri S, Di Mario C, et al. Interleukin-6 and IgA-rheumatoid factor are crucial for baseline erosiveness, and anti-citrullinated peptide antibodies for radiographic progression in early rheumatoid arthritis treated according to a treat-to-target strategy. Scand J Rheumatol 2018;47:351–9.
   PubMed Web of Science ®Google Scholar
• Carrier N, Marotta A, de Brum-Fernandes AJ, Liang P, Masetto A, Ménard HA, et al. Serum levels of 14-3-3η protein supplement C-reactive protein and rheumatoid arthritis-associated antibodies to predict clinical and radiographic outcomes in a prospective cohort of patients with recent-onset inflammatory polyarthritis. Arthritis Res Ther 2016;18:37.
   PubMed Web of Science ®Google Scholar
• Hirata S, Marotta A, Gui Y, Hanami K, Tanaka Y. Serum 14-3-3η level is associated with severity and clinical outcomes of rheumatoid arthritis, and its pretreatment level is predictive of DAS28 remission with tocilizumab. Arthritis Res Ther 2015;17:280.
   PubMed Web of Science ®Google Scholar
• Guan S-Z, Yang Y-Q, Bai X, Wang Y, Feng K-Q, Zhang H-J, et al. Serum 14-3-3η could improve the diagnostic rate of rheumatoid arthritis and correlates to disease activity. Ann Clin Lab Sci 2019;49:57–62.
   PubMed Web of Science ®Google Scholar